Introduction

MCO

Molecular and Clinical Oncology

2049-9450 2049-9469

D.A. Spandidos

MCO-0-0-02413

10.3892/mco.2021.2413

Articles

Expression of VEGF, EGF and HGF in early- and late-stage colorectal cancer

Abdulla

Maha-Hamadien

1 Shaik

Asma Sultana

2 Vaali-Mohammed

Mansoor-Ali

1 Al Khayal

Khayal Abdulmalik

1 Traiki

Thamer Bin

1 Zubaidi

Ahmad Mohammed

1 Al-Johani

Tariq

3 Shakoor

Zahid

4 Al-Obeed

Omar Abdullah

1Colorectal Research Chair, Department of Surgery, King Khalid University Hospital, College of Medicine, King Saud University, Riyadh 11472, Saudi Arabia 2Prince Naif Health Research Centre, King Saud University, Riyadh 11472, Saudi Arabia 3Department of Pathology and Laboratory Medicine, College of Medicine, King Saud University Medical City, Riyadh 11472, Saudi Arabia 4Department of Immunology, King Saud University Medical City, Riyadh 11472, Saudi Arabia

Correspondence to: Dr Maha-Hamadien Abdulla, Colorectal Research Chair, Department of Surgery, King Khalid University Hospital, College of Medicine, King Saud University, Building 4, Exit 2, P.O. Box 7805(37), Riyadh 11472, Saudi Arabia mabdulla@ksu.edu.sa

Abbreviations: CRC, colorectal cancer; EGF, epidermal growth factor; HGF, hepatocyte growth factor; VEGF, vascular endothelial growth factor

12 2021

08 10 2021

15 6

251

12 08 2020 17 03 2021

2020

The heterogenous nature of colorectal cancer (CRC) highlights the need for a better understanding of the growth factors that affect tumour growth and cancer progression. The aim of the present study was to evaluate the role of epidermal growth factor (EGF), vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) in the early (I and II) and late (III and IV) stages of CRC. The serum levels and mRNA expression (n=30) of the aforementioned growth factors were measured and immunohistochemistry (n=20) was performed in patients with CRC. Histological examination revealed comparable distribution of early-stage [I: 8 (26.7%) and II: 7 (23.3%)] and late-stage [III: 8 (26.7%) and IV: 7 (23.3%)] CRC. The mean serum concentrations of VEGF during the early (152.9±14.5 vs. 88.39±3.99 pg/ml; P=0.001) and late (182.7±25.8 vs. 88.39±3.99 pg/ml; P=0.002) stages were significantly higher compared with those in controls. Similarly, the mean serum concentrations of EGF in the early (409.4±7.96 vs. 153.7±13.8 pg/ml; P=0.05) and HGF in the late (90.4±17.4 vs. 56.9±4.97 pg/ml; P=0.05) stages were significantly higher compared with those in controls. The serum concentrations of VEGF, EGF and HGF were comparable between the early and late stages of CRC. Compared to normal tissues, the mRNA expression of both VEGF (P<0.001) and HGF (P<0.01) was upregulated in early-stage and downregulated in late-stage CRC. The expression of EGF remained significantly elevated during both the early and late stages of CRC (P<0.01). Histopathological analyses confirmed increased expression of VEGF in cancerous tissues compared with that in normal tissues. The present study emphasized the need for monitoring the serum levels and tissue expression of growth factors to fully elucidate their role in patients with CRC.

colorectal cancer early stage late stage VEGF EGF HGF expression

Introduction

Colorectal cancer (CRC) is the third most frequent among all types of cancer, comprising an estimated 8-9% of all cancer cases reported in 2020 worldwide (1). In Saudi Arabia, CRC accounts for 14.1% of all cancer-related deaths (2). The local incidence of CRC is on the rise, affecting men more frequently than women (3) and being more frequently diagnosed in young adults (4).

The heterogenous nature of CRC emphasizes the need for a better understanding the of cellular and molecular factors in the tumour microenvironment that regulate tumour cell proliferation and metastasis (5). Alterations in the expression of growth factors and their receptors profoundly affect the proliferation of cancer cells, development of vasculature (angiogenesis) and spread to other organs (6). Signals generated by growth factors modify the tumour microenvironment at various stages of cancer progression (7,8). Low levels of growth factors in biological fluids during the initial stages of cancer development tend to increase rapidly as cancer progresses (9). Certain growth factors, such as epidermal growth factor (EGF), hepatocyte growth factor (HGF) and vascular endothelial growth factor (VEGF), exhibit a robust association with cancer progression (10).

Overexpression of EGF receptor (EGFR) in 60-80% of colonic tumours has been associated with poor prognosis (11). The interaction of EGFR with EGF and TGFα promotes tumourigenesis by dysregulation of the cell cycle, resulting in enhanced tumour cell survival (12). Furthermore, TGFα interaction with EGFR has been shown to promote the expression of VEGF (12), and elevated serum levels of VEGF have been associated with shorter disease-free survival among patients with CRC (13); this may be due to VEGF-mediated angiogenesis through the proliferation, differentiation and migration of vascular endothelial cells (14). Increased serum levels of HGF among patients with cancer, including patients with CRC, have been associated with disease progression (15-17), most likely due to its ability to promote angiogenesis in tumours (18).

The literature indicates that the growth factors EGF, VEGF and HGF may play important roles in determining cancer progression. Since EGF induces VEGF production and HGF regulates EGF expression (11-17), simultaneous assessment of these three growth factors may indicate how they vary at different stages of CRC. Therefore, the present study was performed to assess the serum levels of EGF, VEGF and HGF, along with their mRNA and protein expression, in patients with early- and late-stage CRC.

Materials and methods <sec> <title>Study population

The present study was performed between March 2015 and September 2016 at King Khalid University Hospital, King Saud University (Riyadh, Saudi Arabia). The study protocol was approved by the Institutional Review Board of the College of Medicine, King Saud University. After obtaining written informed consent, blood samples and tissue specimens were collected from a total of 30 patients [14 men (46.7%) and 16 women (53.3%); mean age, 60 years; range, 38-80 years]. Early-stage CRC was defined as stages I and II, whereas late-stage CRC was defined as stages III and IV. Patient demographic and clinical characteristics, including the tumour site and type, were recorded. Tumour staging was performed according to the Union for International Cancer Control (UICC)-TNM staging system; tumour localization, UICC stage and tumour grade were classified as described previously (19). Patients receiving neoadjuvant or adjuvant therapy were excluded from the study.

Blood and tissue samples

A 5-ml venous blood sample was obtained under aseptic conditions from each patient and from age- and sex-matched healthy controls (n=30). Healthy blood samples were obtained from Blood Bank Unit, King Khalid University Hospital (Riyadh, Saudi Arabia). The blood samples were allowed to clot for 1 h at room temperature and were centrifuged at 1,000 x g for 10 min at room temperature to collect the serum. All serum samples were then stored at -80˚C until further use. Cancer and adjacent normal tissue samples (at least 10 cm away from the tumour site) were obtained from the patients, freeze-dried in liquid nitrogen and stored at -80˚C until histological examination.

Measurement of serum concentrations of VEGF, EGF and HGF

The serum concentrations of VEGF, EGF and HGF in patients and controls were quantified using a Human Cytokine multiplex panel (LHC6003, Novex, Invitrogen; Thermo Fisher Scientific, Inc.) and the plates were read using Milliplex™ Luminex xMAP technology (EMD Millipore). The assay was performed in accordance with the manufacturer's instructions. Assessments of standards, internal controls and samples were performed in duplicates and the results are expressed in pg/ml.

Preparation of total RNA and reverse transcription (RT)

RNA was extracted from paired tumour and adjacent healthy tissues using PARIS™ kit (Ambion; Thermo Fisher Scientific, Inc.). Reverse transcription was performed as per the manufacturer's instructions using a high-capacity cDNA kit (cat. no. 4368814; Applied Biosystems; Thermo Fisher Scientific, Inc.). The quality of RNA was evaluated by calculating the A260/280 ratio (1.8-2.0).

Quantitative (q)PCR) analysis

qPCR was performed on ViiA™ 7 Real-Time PCR system (Thermo Fisher Scientific, Inc.) using the SYBR Green PCR Master Mix (cat. no. 4385612; Thermo Fisher Scientific, Inc.). The relative mRNA levels of EGF, HGF and VEGF were normalized to GAPDH in order to estimate their expression in tumour and adjacent normal tissues. The qPCR conditions were 95˚C for 15 min, 40 cycles of 94˚C for 15 sec, and 57˚C for 30 sec. The following primers were used: Human EGF, 5'-GGAATTCTACTTGTGTGGGTCCT-3' (sense) and 5'-TCACTGAGACACCAGCATCC-3' (antisense); human HGF, 5'-GACGCAGCTACAAGGGAACA-3' (sense) and 5'-GCTCGAAGGCAAAAAGCTG-3' (antisense); human VEGF, 5'-TGTGAATGCAGACCAAAGAAAGAT-3' (sense) and 5'-GCTCCAGGGCATTAGACAGC-3' (antisense); and human GAPDH, 5'-ACCCATCACCATCTTCCAGGAG-3' (sense) and 5'-GAAGGGGCGGAGATGATGAC-3' (antisense). The results were normalized to GAPDH levels and the relative expression was calculated with the 2^-∆∆Cq method (20).

Construction of tissue microarrays (TMAs) and immunohistochemistry

TMAs were constructed and immunohistochemistry was performed as described previously (21). VEGF expression was detected using streptavidin-biotinylated horseradish peroxidase (S-ABC) kit cat. no. 65306; NovoLink Max Polymer Detection System; Leica Microsystems, Ltd.) as per the manufacturer's instructions. Negative controls without the primary antibody were also included. The expression of VEGF in tumour and normal tissue was analyzed with the eSlide capture device (ScanScope CS; Aperio Technologies, Inc.). VEGF staining intensity was evaluated as negative, weak or strong and a semi-quantitative analysis was performed based on the categorization of patient samples by staining intensity (22).

Statistical analysis

Statistical analyses were performed using GraphPad Prism 6 (GraphPad Software, Inc.). Data are presented as mean ± standard error. A paired t-test was used to compare growth factor serum and mRNA levels between early- and late-stage CRC. P<0.05 was considered to indicate statistically significant differences.

Results <sec> <title>Patients

A total of 30 patients with CRC [14 men (46.7%) and 16 women (53.3%); mean age, 60 years; range, 38-80 years] were included in the study. Histological examination indicated comparable distribution of early-stage [I: n=8 (26.7%) and II: n=7 (23.3%)] and late-stage [III: n=8 (26.7%) and IV: n=7 (23.3%)] CRC. The characteristics of the patients and clinicopathological data are summarised in Table I.

Serum levels of VEGF, EGF and HGF

The serum concentrations of VEGF, EGF and HGF were compared between patients with early- and those with late-stage CRC and between patients and controls (Table II). Among patients with CRC, the mean serum concentrations of VEGF during the early (152.9±14.5 vs. 88.39±3.99 pg/ml; P=0.001) and late (182.7±25.8 vs. 88.39±3.99 pg/ml; P=0.002) stages of the disease were significantly higher compared with those in controls. Similarly, the mean serum concentrations of EGF among patients with early-stage (409.4±7.96 vs. 153.7±13.8 pg/ml; P=0.05) and late-stage (669.5±13.1 vs. 153.7±13.8 pg/ml) CRC were higher compared with those controls. The mean serum concentrations of HGF did not differ significantly between patients with early-stage CRC and controls (83.54±14.4 vs. 56.9±4.97 pg/ml; P=0.13); however, the levels of HGF were higher in patients with late-stage CRC compared with controls (90.4±17.4 vs. 56.9±4.97 pg/ml; P=0.05). There was no statistically significant difference in the mean serum concentrations of VEGF, EGF and HGF between early- and late-stage CRC.

Gene expression of VEGF, EGF and HGF in patients with CRC

Relative quantification of growth factor expression in early-stage cancer indicated a substantial upregulation in the levels of VEGF (P<0.001), EGF (P<0.05) and HGF (P<0.01) in early-stage CRC compared to adjacent normal tissues (Fig. 1A). However, decreased expression levels of VEGF and HGF were observed in late-stage CRC compared with the levels observed in the early stages, whereas the levels of EGF remained significantly elevated during both the early and late stages of CRC (P<0.01 vs. control; Fig. 1B).

Protein expression of VEGF in patients with CRC

Immunohistochemical analysis of VEGF expression was performed on TMAs of paired tumour and adjacent normal specimens (n=20). Increased expression of VEGF (brown staining) was confirmed in cancerous tissues compared with that in normal tissues (Fig. 2A-C). Early-stage (I and II) tumour tissues exhibited a higher number of VEGF-positive tumour cells (Fig. 2A) compared with late-stage (III and IV) tumour tissues (Fig. 2B). A semi-quantitative analysis was also performed based on the staining intensity of VEGF as negative, weak or strong. Strong staining was observed in 47% of late-stage CRC samples, whereas 53% of the early-stage samples exhibited strong staining. While all tumours displayed VEGF positivity, the intensity of staining varied from weak to strong between early and late cancer stages, and also within the same stage, demonstrating heterogeneous expression.

Discussion

Growth factors in cancer are well known to stimulate cellular proliferation, tumour progression, angiogenesis and subsequent metastasis (6). Increased expression of growth factors is frequently encountered in neoplastic/cancerous cells (23). This may have potential clinical implications in the management and outcome of CRC, as a number of growth factors have been shown to serve as prognostic markers in monitoring the response to therapeutic interventions (24). Elevated serum levels of tumour growth factors, such as EGF, VEGF and HGF, have been reported among patients with CRC, whereas these levels tend to decline following effective treatment (25). Moreover, higher preoperative levels of VEGF and HGF have been reported to be associated with recurrence of CRC after therapy (26). Targeting these angiogenic factors with biological agents may counteract the tumour-promoting effects of these circulating factors. In the present study, significantly higher serum concentrations of EGF, VEGF and HGF were found among patients with early- and late-stage CRC compared to controls.

Owing to its angiogenic potential, the role of VEGF is considered to be critical in CRC. Significantly higher expression of VEGF has been reported in 50% of patients with CRC compared to its expression in healthy tissues (27). Enhanced expression of VEGF is considered as a poor prognostic marker in CRC (28,29) and is also associated with poor overall survival among affected patients (30). Furthermore, elevated serum levels of VEGF are positively correlated with tumour stage, with significantly higher levels of circulating VEGF observed in advanced stages of CRC compared to early stages (31,32). The results of the present study were consistent with these observations, and the intense expression of VEGF in the later stages of the disease suggested a possible role of VEGF in disease progression. Despite the convincing data linking VEGF with disease progression among patients with CRC, there is however evidence refuting these claims and stating that VEGF has no prognostic significance as a risk factor for CRC progression (33). Moreover, no difference in the serum concentrations of VEGF between patients with CRC and healthy controls has been reported (34). Due to the conflicting reports, investigations of factors, such as the involvement of other members of the VEGF family of growth factors (29,35), the extent of inflammation and the number of tumour-infiltrating lymphocytes in CRC, may be useful in gaining a better understanding of the pathogenesis of CRC.

The serum levels of EGF were found to be significantly elevated in patients with early- and late-stage CRC compared to healthy controls in the present study. Data for EGF among patients with CRC are scarce and, to the best of our knowledge, no previous study has compared EGF levels between the early and late stages of CRC. Elevated serum levels of EGF have been shown to exhibit 80% sensitivity and 65% specificity in the detection of ovarian cancers (36). Increased expression of EGF has not only been associated with various types of cancer, but is also considered to be a poor prognostic marker in terms of adverse clinical outcomes (37-41). By contrast, low levels of EGF have been reported among patients with non-small cell lung cancer and head and neck cancer compared with healthy controls (42). In the present study, however, EGF was found to be markedly elevated in both the early and late stages of CRC, indicating the potential clinical role of this marker. Although studies ascertaining the clinical significance of this finding in CRC are currently lacking, the evidence reported by studies performed on patients with ovarian (36), lung, and head and neck cancers (42) indicate that EGF expression may be of substantial diagnostic value. Further studies are therefore needed to evaluate the diagnostic and/or prognostic significance of this marker in CRC.

HGF and its receptor, c-Met (tyrosine-protein kinase Met or hepatocyte growth factor receptor), are involved in a number of important biological processes (43). HGF/c-Met interaction has been implicated in HGF-activated colonic fibroblast-mediated carcinogenesis of colonic epithelial cancer cells (44,45). The higher levels of c-Met mRNA and protein in CRC liver metastasis, the positive correlation between c-Met expression and liver metastasis, and the association of the downregulation of HGF/c-Met signalling with the reduction in cell proliferation, invasion and metastasis of liver cancer, indicate a potentially crucial role of HGF in CRC (46). Moreover, increased expression of HGF among patients with CRC has been shown to exhibit a positive correlation with disease progression (25). The serum concentration of HGF was found to be higher in the early stages of CRC in the present study, whereas its levels normalized in the late stages. These observations suggest an involvement of HGF in disease pathogenesis in the early stages of CRC, thus highlighting it as a promising target for therapeutic interventions. Furthermore, there appears to be a need for further investigations to elucidate the role of HGF in cancer development, lymphatic invasion and survival in CRC (17).

It is evident that tumour progression from early to late stage involves a number of cellular, biochemical and molecular events, including altered expression of several growth factors (46). However, mRNA expression levels may not be reflective of serum concentrations, possibly owing to post-transcriptional, translational and post-translational modifications, which may determine protein degradation and its regulation (47). Further studies are needed to understand this perspective. Moreover, an increase in the concentrations of growth factors may be associated with an increase in the numbers of cancer niche cells during carcinogenesis, which also needs additional supportive evidence (48). The growth factor expression profile observed in the present study during the early and late stages of CRC offers an opportunity for further investigations to identify targets for predicting the prognosis and establishing therapeutic interventions for the containment of CRC progression.

In conclusion, the elevated levels of growth factors during the early and late stages of CRC observed in the present study highlight the importance of growth factor expression in CRC. However, a major limitation of the present study was its small sample size. Large scale studies are recommended to validate the findings of the present study and to gain a better understanding of the exact role of growth factors in the pathogenesis of CRC.

Acknowledgements

Not applicable.

Funding

The present study was supported and funded by Researchers Supporting Project number (grant no. RSP-2021/344), King Saud University, Riyadh, Saudi Arabia.

Availability of data and materials

The datasets used and/or analysed during the present study are available from the corresponding author upon reasonable request.

Authors' contributions

MHA, OAAO and MAVM conceived and designed the study, and drafted the manuscript; MHA, SAS and MAVM performed the statistical data analysis; MAVM, MHA, SAS and TBT have seen and can confirm the authenticity of the raw data; KAAK, TBT, TAJ, ZS and AMZ were involved in data acquisition and interpretation, and critically revised the manuscript for important intellectual content. All the authors have read and approved the final manuscript.

Ethics approval and consent to participate

The study was approved by the Institutional Review Board of College of Medicine (approval no. 15/0482), King Saud University, and all the participants provided their written informed consent prior to enrolment.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References 1

Siegel

Miller

Jemal

Cancer statistics, 2020

CA Cancer J Clin707302020

31912902

10.3322/caac.21590

Bray

Ferlay

Soerjomataram

Siegel

Torre

Jemal

Global cancer statistics 2018. GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

CA Cancer J Clin683944242018

30207593

10.3322/caac.21492

Ayyub

Al-Radi

Khazeindar

Nagi

Maniyar

Clinicopathological trends in colorectal cancer in a tertiary care hospital

Saudi Med J231601632002

11938390

Mosli

Al-Ahwal

Colorectal cancer in the kingdom of Saudi Arabia: Need for screening

Asian Pac J Cancer Prev13380938132012

23098475

10.7314/apjcp.2012.13.8.3809

Tiash

Chowdhury

Growth factor receptors: Promising drug targets in cancer

J Cancer Metastasis Treat11902002015

Witsch

Sela

Yarden

Roles for growth factors in cancer progression

Physiology (Bethesda)25851012010

20430953

10.1152/physiol.00045.2009

Kantola

Klintrup

Vayrynen

Vornanen

Bloigu

Karhu

Herzig

Napankangas

Mäkelä

Karttunen

Stage-dependent alterations of the serum cytokine pattern in colorectal carcinoma

Br J Cancer107172917362012

23059742

10.1038/bjc.2012.456

Krzystek-Korpacka

Diakowska

Kapturkiewicz

Bębenek

Gamian

Profiles of circulating inflammatory cytokines in colorectal cancer (CRC), high cancer risk conditions, and health are distinct. Possible implications for CRC screening and surveillance

Cancer Lett3371071142013

23726839

10.1016/j.canlet.2013.05.033

Tang

Liao

Song

Shi

Yang

Th1/Th2 cytokine profiles in G+/G- bacteremia in pediatric hematology/oncology patients

Pediatr Blood Cancer5850542012

22076831

10.1002/pbc.22692

Venere

Lathia

Rich

Growth factor receptors define cancer hierarchies

Cancer Cell231351372013

23410969

10.1016/j.ccr.2013.01.020

Cohen

Epidermal growth factor receptor as a therapeutic target in colorectal cancer

Clin Colorectal Cancer22462512003

12620146

10.3816/CCC.2003.n.006

Pabla

Bissonnette

Konda

Colon cancer and the epidermal growth factor receptor: Current treatment paradigms, the importance of diet, and the role of chemoprevention

World J Clin Oncol61331412015

26468449

10.5306/wjco.v6.i5.133

Cascinu

Staccioli

Gasparini

Giordani

Catalano

Ghiselli

Rossi

Baldelli

Graziano

Saba

Expression of vascular endothelial growth factor can predict event-free survival in stage II colon cancer

Clin Cancer Res6280328072000

10914727

Rapisarda

Melillo

Role of the VEGF/VEGFR axis in cancer biology and therapy

Adv Cancer Res1142372672012

22588059

10.1016/B978-0-12-386503-8.00006-5

Gohji

Nomi

Niitani

Kitazawa

Fujii

Katsuoka

Nakajima

Independent prognostic value of serum hepatocyte growth factor in bladder cancer

J Clin Oncol18296329712000

10944129

10.1200/JCO.2000.18.16.2963

Naughton

Picus

Zhu

Catalona

Vollmer

Humphrey

Scatter factor-hepatocyte growth factor elevation in the serum of patients with prostate cancer

J Urol165132513282001

11257710

Toiyama

Miki

Inoue

Okugawa

Tanaka

Kusunoki

Serum hepatocyte growth factor as a prognostic marker for stage II or III colorectal cancer patients

Int J Cancer125165716622009

19569242

10.1002/ijc.24554

Hanzawa

Shindoh

Higashino

Yasuda

Inoue

Hida

Ono

Kohgo

Nakamura

Notani

Hepatocyte growth factor upregulates E1AF that induces oral squamous cell carcinoma cell invasion by activating matrix metalloproteinase genes

Carcinogenesis21107910852000

10836994

Sobin

Compton

TNM seventh edition: What's new, what's changed: Communication from the International Union Against Cancer and the American Joint Committee on Cancer

Cancer116533653392010

20665503

10.1002/cncr.25537

Livak

Schmittgen

Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method

Methods254024082001

11846609

10.1006/meth.2001.1262

Al Obeed

Alkhayal

Al Sheikh

Zubaidi

Vaali-Mohammed

Boushey

McKerrow

Abdulla

Increased expression of tumour necrosis factor-alpha is associated with advanced colorectal cancer stages

World J Gastroenterol2018390183962014

25561807

10.3748/wjg.v20.i48.18390

Al Obeed

Alkhayal

Al Sheikh

Zubaidi

Vaali-Mohammed

Boushey

Mckerrow

Abdulla

Increased expression of tumor necrosis factor-α is associated with advanced colorectal cancer stages

World J Gastroenterol2018390183962014

25561807

10.3748/wjg.v20.i48.18390

Hanahan

Weinberg

Hallmarks of cancer: The next generation

Cell1446466742011

21376230

10.1016/j.cell.2011.02.013

De Divitiis

Nasti

Montano

Fisichella

Iaffaioli

Berretta

Prognostic and predictive response factors in colorectal cancer patients: Between hope and reality

World J Gastroenterol2015049150592014

25386053

10.3748/wjg.v20.i41.15049

Inanc

Karaca

Berk

Ozkan

Saraymen

Elmali

Prognostic value of tumour growth factor levels during chemotherapy in patients with metastatic colorectal cancer

Med Oncol29311931242012

22580817

10.1007/s12032-012-0250-8

Yoon

Kim

Gonen

Heffernan

Detwiller

Jarnagin

D'Angelica

Blumgart

Tanabe

Dematteo

Profile of plasma angiogenic factors before and after hepatectomy for colorectal cancer liver metastases

Ann Surg Oncol133533622006

16474912

10.1245/ASO.2006.03.060

Bendardaf

Buhmeida

Hilska

Laato

Syrjänen

Collan

Pyrhönen

VEGF-1 expression in colorectal cancer is associated with disease localization, stage, and long-term disease-specific survival

Anticancer Res28386538702008

19192642

Liu

Duan

Cheng

Chen

Xie

Long

Lin

Zhu

IL-17 is associated with poor prognosis and promotes angiogenesis via stimulating VEGF production of cancer cells in colorectal carcinoma

Biochem Biophys Res Commun4073483542011

21396350

10.1016/j.bbrc.2011.03.021

Martins

Garcia

Luz

Pardal

Rodrigues

Filho

Clinicopathological correlation and prognostic significance of VEGF-A, VEGF-C, VEGFR-2 and VEGFR-3 expression in colorectal cancer

Cancer Genomics Proteomics1055672013

23603341

Des Guetz

Uzzan

Nicolas

Cucherat

Morere

Benamouzig

Breau

Perret

Microvessel density and VEGF expression are prognostic factors in colorectal cancer. Meta-analysis of the literature

Br J Cancer94182318322006

16773076

10.1038/sj.bjc.6603176

Kwon

Kim

Lee

Han

Kim

Goh

Choi

Park

Roh

Clinical significance of preoperative serum vascular endothelial growth factor, interleukin-6, and C-reactive protein level in colorectal cancer

BMC Cancer102032010

20465852

10.1186/1471-2407-10-203

Eldesoky

Shouma

Mosaad

Elhawary

Clinical relevance of serum vascular endothelial growth factor and interleukin-6 in patients with colorectal cancer

Saudi J Gastroenterol171701732011

21546718

10.4103/1319-3767.80378

Lee

Chow

Wang

Huang

Prognostic value of vascular endothelial growth factor expression in colorectal cancer patients

Eur J Cancer367487532000

10762747

10.1016/s0959-8049(00)00003-4

Coşkun

Öztopuz

Özkan

ÖF

Determination of IL-6, TNF-α and VEGF levels in the serums of patients with colorectal cancer

Cell Mol Biol (Noisy-le-grand)63971012017

28719352

10.14715/cmb/2017.63.5.18

George

Tutton

Janssen

Arnaout

Abulafi

Eccles

Swift

VEGF-A, VEGF-C, and VEGF-D in colorectal cancer progression

Neoplasia34204272001

11687953

10.1038/sj.neo.7900186

Balcan

Demirkiran

Aydin

Sanioglu

Bese

Arvas

Akçay

Cift

Serum levels of epidermal growth factor, transforming growth factor, and c-erbB2 in ovarian cancer

Int J Gynecol Cancer22113811422012

22914212

10.1097/IGC.0b013e31825b7dcc

Spano

Lagorce

Atlan

Milano

Domont

Benamouzig

Attar

Benichou

Martin

Morere

Impact of EGFR expression on colorectal cancer patient prognosis and survival

Ann Oncol161021082005

15598946

10.1093/annonc/mdi006

Cheirsilpa

Ruangvejvorachai

Karalak

Sangprakarn

Pummai

Sangrajrang

Determination of epidermal growth factor receptor (EGFR) in patients with colorectal cancer

Cancer Ther51371422007

Arteaga

The epidermal growth factor receptor: From mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia

J Clin Oncol19 (Suppl 18)S32S402001

11560969

Yarden

The EGFR family and its ligands in human cancer. Signalling mechanisms and therapeutic opportunities

Eur J Cancer37 (Suppl 4)S3S82001

11597398

10.1016/s0959-8049(01)00230-1

Goldstein

Armin

Epidermal growth factor receptor immunohistochemical reactivity in patients with American Joint committee on cancer stage IV colon adenocarcinoma: Implications for a standardized scoring system

Cancer92133113462001

11571750

10.1002/1097-0142(20010901)92:5<1331::aid-cncr1455>3.0.co;2-m

Lemos-Gonzalez

Rodriguez-Berrocal

Cordero

Gómez

Paez de la Cadena

Alteration of the serum levels of the epidermal growth factor receptor and its ligands in patients with non-small cell lung cancer and head and neck carcinoma

Br J Cancer96156915782007

17453000

10.1038/sj.bjc.6603770

Kermorgant

Zicha

Parker

PKC controls HGF-dependent c-Met traffic, signalling and cell migration

EMBO J23372137342004

15385963

10.1038/sj.emboj.7600396

Zhu

HGF-activated colonic fibroblasts mediates carcinogenesis of colonic epithelial cancer cells via PKC-cMET-ERK1/2-COX-2 signaling

Cell Signal278608662015

25643632

10.1016/j.cellsig.2015.01.014

Yao

Yan

Zheng

Wang

Zhou

Zhang

Wei

Sun

Role of HGF/c-Met in the treatment of colorectal cancer with liver metastasis

J Biochem Mol Toxicol33e223162019

30897285

10.1002/jbt.22316

Easton

Eeles

Genome-wide association studies in cancer

Hum Mol Genet17R109R1152008

18852198

10.1093/hmg/ddn287

Vogel

Marcotte

Insights into the regulation of protein abundance from proteomic and transcriptomic analyses

Nat Rev Genet132272322012

22411467

10.1038/nrg3185

Plaks

Kong

Werb

The cancer stem cell niche: How essential is the niche in regulating stemness of tumour cells?

Cell Stem Cell162252382015

25748930

10.1016/j.stem.2015.02.015

Figure 1

Relative quantification of growth factor expression normalized to GAPDH in (A) early-stage and (B) late-stage colorectal cancer. ^*P<0.05, ^**P<0.01 and ^***P<0.001 vs. control. EGF, epidermal growth factor; VEGF, vascular endothelial growth factor; HGF, hepatocyte growth factor.

Figure 2

Immunohistochemistry staining for VEGF. (A) Photomicrograph showing normal mucosa with negative staining for VEGF. (B) Colonic adenocarcinoma exhibiting strong positive epithelial neoplastic luminal staining for VEGF in a patient with early-stage disease. (C) Colonic adenocarcinoma exhibiting weak staining for VEGF in a patient with late-stage disease. Magnification, x600.

Table I

Clinicopathological characteristics of patients with colorectal cancer.

Variables	Number of patients	Percentage
Mean age (years)
≤60	17	56.7
>60	13	33.3
Sex
Male	14	46.7
Female	16	53.3
Primary tumour
Colon	27	90
Rectum	3	10
Tumour stage (UICC 2010)
pT1	4	13.3
pT2	8	26.7
pT3	15	50
pT4	3	10
Lymph node status (UICC 2010)
pN0	15	50
pN1	13	43.3
pN2	2	6.7
Clinical stage (UICC 2010)
I	8	26.7
II	7	23.3
III	8	26.7
IV	7	23.3
Histological grade (UICC 2010)
G1	0	0
G2	28	93.3
G3	2	6.7

UICC, Union for International Cancer Control.

Table II

Comparison of serum levels of growth factors between patients with CRC and healthy controls.

		CRC		P-value
Growth factors	Controls	Early-stage	Late-stage	Control vs. early-stage CRC	Control vs. late-stage CRC	Early- vs. late-stage CRC
VEGF	88.39±3.99	152.9±14.5	182.7±25.8	0.0012^c	0.002^b	0.291
EGF	153.7±13.8	409.4±7.96	669.5±13.1	0.05^a	0.01^b	0.08
HGF	56.9±4.97	83.54±14.4	90.4±17.4	0.13	0.05^a	0.762

Values are provided in pg/ml and are presented as mean ± SD.

^aP≤0.05;

^bP≤0.01;

^cP≤0.001. EGF, epidermal growth factor; VEGF, vascular endothelial growth factor; HGF, hepatocyte growth factor; CRC, colorectal cancer.